Akademik Veri Yönetim Sistemi
31. Avrupa Gen ve Hücre Tedavi Kongresi, Rome, İtalya, 22 - 27 Ekim 2024, ss.1-2, (Özet Bildiri)
The urgent need for a safe and effective vaccine against COVID-19, caused by the SARS-CoV-2 virus, has driven the exploration of various vaccine platforms. Among these, viral vector-based vaccines, particularly those utilizing adenovirus vector, offer significant advantages. Adenovirusbased vectors are characterized by their broad tissue tropism, well-understood vector genome, high transgene capacity, natural adjuvant effect, and ability to induce robust transgene-specific T cell and B cell responses. This study focuses on the development of a human adenoviral vector based on Serotype 5 encoding the SARS-CoV-2 Spike protein as potential vaccine candidates. Using Gateway® Cloning Technology, we constructed a human adenoviral vector encoding the SARS-CoV-2 Spike protein (Ad5Spike). The Ad5Spike vaccine vector was generated by transient transfection of the pAd5Spike expression plasmid into 293A cells via the calcium phosphatemediated method. Post-transfection, the Ad5Spike virus was purified and concentrated through cesium chloride density gradient ultracentrifugation. For immunization, the vector was intraperitoneally injected at different concentrations (108, 1010, and 1012 viral particles) into 6- 8-week-old female BALB/c mice in 10 mM Tris-Cl buffer. Both cellular and humoral immune responses were evaluated at 30- and 90-days post-immunization using ELISA, ELISpot, and neutralization assays. To assess the humoral immune response IgG ELISA was performed and these mice exhibited producing of serum anti-spike IgG. Furthermore, IL-2, TNF-α, and IFN-γ sytocines were significantly higher compared to the control groups. Espesically cytotoxic T cell responses (IL-2 and IFN-γ) were detected even at 90 days post-vaccination. Finally, neutralization tests conducted using 3rd generation lentiviral-based pseudovirus demonstrated that the vaccinated mice, particularly those in the high dose group, were effectively protected against potential viral infection and exhibited strong neutralizing activity against SARSCoV-2 in splenocytes. In conclusion, the development of the Ad5Spike vectors shows great promise as a vaccine candidate against COVID-19. The ability of this vaccine to induce both humoral and cellular immunity suggests its potential to provide protective immunity for at least 90 days against SARS-CoV-2 (This study is supported by grants from Akdeniz University Scientific Administration Division, Grant No. TDK-2022-6067).